共 50 条
- [1] RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC)ANNALS OF ONCOLOGY, 2022, 33 : S375 - S375Yoon, H.Kato, K.Raymond, E.Hubner, R.Shu, Y.Pan, Y.Jiang, Y.Zhang, J.Park, S.Kojima, T.Lin, C.Gotovkin, E.Wyrwicz, L.Ishihara, R.Li, L.Tao, A.Shi, J.Wang, L.Xu, J.
- [2] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 studyLANCET ONCOLOGY, 2023, 24 (05): : 483 - 495Xu, JianmingKato, KenRaymond, EricHubner, Richard A.Shu, YongqianPan, YueyinPark, Sook RyunPing, LuJiang, YiZhang, JingdongWu, XiaohongYao, YuanhuShen, LinKojima, TakashiGotovkin, EvgenyIshihara, RyuWyrwicz, LucjanVan Cutsem, EricJimenez-Fonseca, PaulaLin, Chen -YuanWang, LeiShi, JingwenLi, LiyunYoon, Harry H.
- [3] Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-upJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Yoon, Harry H.Kato, KenRaymond, EricHubner, RichardShu, YongqianPan, YueyinJiang, YiZhang, JingdongPark, Sook RyunKojima, TakashiLin, Chen-YuanWyrwicz, Lucjan S.Tougeron, DavidIshihara, RyuLi, LiyunWu, HongqianPeng, YanyanYan, ShicanXu, Jianming
- [4] Randomized, global, phase III study of tislelizumab (TIS) plus chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroupANNALS OF ONCOLOGY, 2022, 33 : S1458 - S1458Kato, K.Yoon, H.Raymond, E.Hubner, R.Shu, Y.Pan, Y.Park, S. R.Ping, L.Jiang, Y.Zhang, J.Wu, X.Yao, Y.Shen, L.Kojima, T.Lin, C-Y.Wang, L.Tao, A.Peng, Y.Li, L.Xu, J.
- [5] Randomized, global, phase 3 study of tislelizumab (TIS) plus chemotherapy (chemo) versus placebo (PBO) plus chemo as first-line (1L) treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Non-Asia subgroup.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 340 - 340Raymond, EricHubner, RichardGotovkin, EvgenyWyrwicz, LucjanVan Cutsem, EricJimenez-Fonseca, PaulaPazo-Cid, RobertoXu, JianmingKato, KenTao, AiyangWang, LeiPeng, YanyanLi, LiyunYoon, Harry H.
- [6] Randomized, global, phase III study of tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 updateANNALS OF ONCOLOGY, 2023, 34 : S853 - S853Hubner, R.Xu, J.Kato, K.Raymond, E.Shu, Y.Pan, Y.Jiang, Y.Zhang, J.Park, S. R.Kojima, T.Lin, C-Y.Gotovkin, E.Wyrwicz, L. S.Ishihara, R.Wu, H.Peng, Y.Wang, L.Li, L.Yoon, H.
- [7] Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroupJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)Zhao, KuaileKim, Sung-BaeKato, KenHsu, Chih-HungHu, ShengWang, FengKojima, TakashiKim, Young SaingVan Cutsem, EricAjani, Jaffer A.Li, LiyunDing, NingningTao, AiyangShen, Lin
- [8] Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in ChinaRISK MANAGEMENT AND HEALTHCARE POLICY, 2023, 16 : 2447 - 2458Zhou, ChongchongWei, JingxuanXu, KaiLin, YingtaoZhang, LingliLi, Xin
- [10] First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306ADVANCES IN THERAPY, 2025, : 2269 - 2284Xu, JianmingKato, KenHubner, RichardPark, Sook RyunKojima, TakashiIshihara, RyuWyrwicz, LucjanVan Cutsem, EricJimenez-Fonseca, PaulaWu, HongqianWang, LeiYan, SebastianShi, JingwenKadva, AlyshaYoon, Harry H.